Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
OncLive
Loading...
WATCH: Benjamin Croll, MD, of @foxchasecancer.bsky.social discusses research focused on understanding response to systemic therapy in RCC. #oncology #RCC #kcsm
www.onclive.com/view/dr-crol...
WATCH: Mark D. Tyson, II, MD, MPH of @mayocliniccancer.bsky.social discusses data from a real-world study of blue light cystoscopy in high-risk NMIBC. #oncology #NMIBC #bladdercancer
www.onclive.com/view/dr-tyso...
Real-world data from the CIBMTR registry at #EHA2026 reinforce the impact of liso-cel in relapsed/refractory #MCL.
✅ ORR of 89% and CR rate of 79%
✅ Median DOR, PFS, and OS not reached
✅ Safety profile consistent with pivotal trial results
Learn more: www.onclive.com/view/real-wo...
Benjamin Croll, MD, discusses research focused on understanding response to systemic therapy in RCC.
In the BTK inhibitor–naive setting, the BTK degrader tacabrutideg was safe with antitumor activity in CLL and other B-cell malignancies #EHA2026 #leusm #oncology
Read more on cohort 1f of the phase 1 CaDAnCe-101 trial: www.onclive.com/view/tacabru...
Real-world data show liso-cel drives high response rates and durable benefit in relapsed/refractory MCL, including high-risk patients.
Mark D. Tyson, II, MD, MPH, discusses data from a real-world study of blue light cystoscopy in high-risk NMIBC.
www.onclive.com
🦴🚨 The FDA has accepted the BLA for ozekibart (INBRX-109) in patients with unresectable or metastatic conventional chondrosarcoma, marking a major regulatory milestone in a disease with no approved systemic therapies.
Read more ➡️ www.onclive.com/view/fda-acc...
#Sarcoma #Chondrosarcoma #Oncology
The combination of cadonilimab plus axitinib demonstrated promising efficacy and a manageable safety profile as frontline therapy for advanced non–clear cell RCC.
Read more ➡️ www.onclive.com/view/cadonil...
#KidneyCancer #RCC #nccRCC #GUonc #Immunotherapy #kcsm #Oncology
Updated ROCK-1 data at #EHA2026 show that rocbrutinib continues to deliver activity in R/R #MCL previously treated w/ a covalent BTK inhibitor. #lymsm
✅ ORR of 63.9%, including a 23.0% CR rate
✅ Median DOR of 16.46 months
✅ Median OS NR at 23.36 months of follow-up
onclive.com/view/rocbrut...
LB2501, an off-the-shelf in vivo dual-target CAR T-cell therapy, produced a 100% ORR at dose level 2 across DLBCL, MCL, and follicular lymphoma. #EHA2026 #lymsm #hematology
www.onclive.com/view/in-vivo...
Subcutaneous blinatumomab led to high response rates across 2 dosing regimens in heavily pretreated patients with relapsed/refractory, Ph-positive B-ALL in a phase 1/2 trial #EHA2026 #leusm #oncology
Dive into the data: www.onclive.com/view/subcuta...
Tuspetinib/venetoclax/azacitidine produced high CR and MRD-negativity rates across molecular subgroups of older or unfit patients newly diagnosed AML. #EHA2026 #leusm #hematology
www.onclive.com/view/tuspeti...
Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.
